Research programme: nicotinic alpha 6 receptor modulators - Saniona

Drug Profile

Research programme: nicotinic alpha 6 receptor modulators - Saniona

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Saniona
  • Class Small molecules
  • Mechanism of Action Nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 25 Apr 2017 Preclinical trials in Parkinson's disease in Denmark, before April 2017 (Saniona website, April 2017)
  • 21 Jul 2016 Early research in Parkinson's disease in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top